Brief: Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
03/12/2024 12:40
Dec 3 (Reuters) - Aptose Biosciences Inc APS.TO :
* APTOSE SIGNS CRADA WITH NCI TO DEVELOP TUSPETINIB FOR AML
AND
MDS IN NEWLY LAUNCHED MYELOMATCH PRECISION MEDICINE TRIALS
Source text: ID:nGNX7TKtlK
Further company coverage: APS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aptose Biosciences
See all newsBrief: Aptose Biosciences Says Closing Of Arrangement With Hanmi Pharmaceutical Further Delayed
Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting